Enzyme Inhibitors for Oral Peptide Protection
Oral Peptide Drugs
3 classes of enzymatic promoters
Protease inhibitors, mucolytic enzymes, and tight junction openers represent three distinct strategies for overcoming the enzymatic barrier to oral peptide delivery.
Steiger et al., Journal of Controlled Release, 2025
Steiger et al., Journal of Controlled Release, 2025
View as imageA peptide that survives stomach acid still faces an enzymatic gauntlet in the small intestine. Pancreatic proteases, trypsin, chymotrypsin, elastase, and carboxypeptidases, collectively degrade more than 95% of ingested protein within the first 60 centimeters of the duodenum.[1] For therapeutic peptides, this enzymatic destruction is the second major barrier to oral delivery, operating downstream of the acid barrier that enteric coatings address. The broader landscape of oral peptide challenges is covered in the future of oral peptide drugs.
Key Takeaways
- The GI tract contains at least 40 proteases that degrade peptide drugs, with trypsin, chymotrypsin, and elastase being the most destructive in the small intestine (Verma et al., Drug Development Research, 2021)
- A 2025 review categorized enzymatic promoters into three classes: protease inhibitors, mucolytic enzymes, and tight junction openers (Steiger et al., Journal of Controlled Release, 2025)
- Soybean trypsin and chymotrypsin inhibitors significantly reduced degradation of the peptide thymopentin in ex vivo intestinal models (Liu et al., International Journal of Pharmaceutics, 2022)
- A single aza-amino acid substitution made GLP-1 and GIP agonists completely resistant to DPP4 degradation while retaining full receptor potency (Dinsmore et al., Angewandte Chemie, 2024)
- Even with enzyme inhibitors plus other delivery strategies, oral peptide bioavailability remains below 10% in most preclinical studies (Jianghao et al., Food Chemistry, 2026)
- Co-encapsulation of enzyme inhibitors with peptide drugs in nanoparticles can protect both the drug and the inhibitor from premature degradation (Li et al., Bioactive Materials, 2022)
The enzymatic barrier explained
The gastrointestinal tract evolved to break proteins into individual amino acids for absorption. This is precisely the opposite of what oral peptide drug delivery requires: getting an intact, folded peptide through the gut and into the bloodstream.
Three classes of proteases operate in sequence along the GI tract.[1]
Gastric proteases. Pepsin, activated at pH 1-3, is a broad-specificity aspartyl protease that cleaves peptide bonds preferentially near hydrophobic amino acids. Pepsin alone can reduce a peptide's biological activity by more than 90% within minutes of gastric exposure.
Pancreatic proteases. Upon entry into the duodenum, peptides encounter a concentrated cocktail of serine proteases secreted by the pancreas. Trypsin cleaves after arginine and lysine residues. Chymotrypsin targets aromatic and large hydrophobic residues. Elastase cuts at small hydrophobic residues. Carboxypeptidases A and B remove amino acids sequentially from the C-terminus. Together, these enzymes can reduce a 20-amino-acid peptide to fragments too small to retain receptor binding activity in less than 15 minutes.
Brush border enzymes. The intestinal epithelial surface is studded with membrane-anchored peptidases, including aminopeptidase N, dipeptidyl peptidase IV (DPP4), and angiotensin-converting enzyme (ACE). These enzymes process the fragments left by pancreatic proteases, and also degrade intact peptides that reach the intestinal wall. DPP4 is particularly relevant because it is the enzyme that rapidly inactivates GLP-1, the endogenous peptide that GLP-1 agonist drugs are designed to mimic.
A 2022 ex vivo study mapped the degradation of thymopentin (TP5) across the entire intestinal tract. Degradation followed pseudo-first-order kinetics and was primarily driven by luminal enzymes rather than brush border enzymes. The duodenum and jejunum were the most destructive segments, with the ileum and colon showing progressively lower proteolytic activity.[2]
Strategies for blocking digestive enzymes
A 2025 review in the Journal of Controlled Release organized enzymatic approaches into three categories, each operating through a different mechanism.[3]
Classical protease inhibitors
The most direct approach is co-administering protease inhibitors alongside the peptide drug. These inhibitors bind to the active sites of GI proteases, temporarily blocking their ability to cleave peptide bonds.
Aprotinin (also known as bovine pancreatic trypsin inhibitor, or BPTI) is a 58-amino-acid polypeptide originally isolated from bovine lung tissue. It inhibits trypsin, chymotrypsin, and plasmin with nanomolar affinity. Aprotinin was among the first protease inhibitors tested for oral peptide delivery, with early studies in the 1990s showing it could improve oral insulin absorption in animal models when co-administered at high concentrations.
Soybean trypsin inhibitors come in two forms: the Kunitz-type inhibitor (a 20 kDa protein that primarily targets trypsin) and the Bowman-Birk inhibitor (an 8 kDa protein that simultaneously inhibits both trypsin and chymotrypsin through two independent binding sites). The dual inhibition profile of Bowman-Birk inhibitors makes them particularly attractive for oral peptide protection because they neutralize the two most destructive pancreatic proteases at once.
In the thymopentin degradation study, soybean trypsin and chymotrypsin inhibitors significantly reduced TP5 breakdown across all intestinal segments tested.[2] The protection was greatest in the duodenum and jejunum, precisely where enzymatic activity was highest, suggesting that co-localization of the inhibitor with the region of greatest enzymatic threat is critical.
Camostat mesylate is a synthetic serine protease inhibitor that blocks trypsin, chymotrypsin, and kallikrein. It is orally bioavailable itself, which is an advantage over protein-based inhibitors that are also subject to proteolytic degradation. Camostat has been tested as a co-administered agent for oral insulin delivery in preclinical models.
The paradox of protein-based inhibitors
Natural protease inhibitors like aprotinin and soybean trypsin inhibitors face an inherent problem: they are themselves proteins and are therefore subject to degradation by the same enzymes they are meant to inhibit. In the GI tract, a protein-based protease inhibitor competes with the peptide drug for enzymatic attack. This means the inhibitor must be present in large excess to saturate the proteases before the drug is destroyed. A 2021 review noted that natural protease inhibitors must be administered in "large quantity" or co-encapsulated in protective carriers to overcome their own susceptibility to enzymatic degradation.[1]
This limitation has driven interest toward two alternative approaches: small molecule protease inhibitors that are not themselves degraded by proteases, and nanoparticle systems that co-encapsulate the peptide drug and the protease inhibitor within a protective shell.
Nanoparticle co-encapsulation
A 2022 review of nanoparticle-based oral peptide delivery systems described how polymer nanoparticles, liposomes, and solid lipid nanoparticles can simultaneously carry the therapeutic peptide and protease inhibitors within the same particle.[4] This co-encapsulation addresses the paradox above: the protective shell shields both the drug and the inhibitor from premature degradation until the particle reaches its target site in the intestine.
pH-responsive nanoparticles take this further by remaining sealed at gastric pH and releasing their payload (peptide drug plus enzyme inhibitor) only at intestinal pH. When the particle opens, the locally released enzyme inhibitor creates a protective microenvironment around the peptide, buying time for absorption before proteases can attack.[5]
Designing peptides that resist enzymes
Rather than adding external protease inhibitors, an alternative strategy is engineering the peptide drug itself to resist enzymatic cleavage. This approach eliminates the need for co-administered inhibitors and their associated formulation complexity.
DPP4-resistant modifications
GLP-1, the endogenous incretin peptide, has a half-life of approximately 2 minutes in the bloodstream because DPP4 cleaves the alanine-glutamate bond at position 2. All marketed GLP-1 receptor agonists incorporate modifications that resist this cleavage: semaglutide uses an alpha-aminoisobutyric acid substitution at position 2, while exenatide derives from exendin-4, a lizard peptide that naturally lacks the DPP4 cleavage site.
A 2024 study demonstrated that a single aza-amino acid substitution (replacing a carbon atom with nitrogen in the peptide backbone) at position 2 made both GLP-1 and GIP agonists completely resistant to DPP4 while retaining full receptor potency and efficacy. Molecular dynamics simulations showed that the nitrogen substitution forced a conformational change that prevented the peptide from fitting into DPP4's active site.[6]
Broader backbone modifications
Beyond DPP4 resistance, structural modifications can provide resistance to the full spectrum of GI proteases. D-amino acid substitution, N-methylation, cyclization, and PEGylation each reduce protease recognition through different mechanisms. A 2023 review of oral peptide delivery systems noted that these chemical modifications can be combined with formulation strategies (enteric coatings, permeation enhancers, enzyme inhibitors) in multi-layer approaches.[7]
The trade-off is that modifications that reduce protease recognition can also reduce receptor binding. Each amino acid substitution or backbone change must be tested for its impact on both enzymatic stability and biological activity. A modification that makes a peptide protease-proof but eliminates receptor binding is pharmacologically useless.
How enzyme inhibitors fit into multi-barrier strategies
No single strategy achieves sufficient oral bioavailability for peptide drugs on its own. A 2026 review emphasized that integrated multi-barrier approaches are required because the GI tract presents at least four sequential obstacles: acid pH, enzymatic degradation, the mucus layer, and epithelial impermeability.[8]
In practice, this means enzyme inhibitors are combined with:
- Enteric coatings that protect against gastric acid
- Permeation enhancers that open tight junctions for paracellular absorption
- Mucoadhesive polymers that hold the formulation near the epithelial surface
- Nanoparticle carriers that protect the drug during transit and enhance uptake
A 2023 case study in dosage form optimization demonstrated that layering a peptide drug with a permeation enhancer in a multi-unit particulate system, combined with enzyme inhibitor co-payload, achieved higher absorption than either strategy alone.[9]
The Mycapssa approach to oral octreotide delivery exemplifies this multi-barrier strategy: enteric coating protects against stomach acid, sodium caprylate enhances intestinal permeation, and the formulation's pH-targeted release ensures the peptide encounters the enzyme-rich duodenal environment for the minimum possible time.[10]
Limitations and open questions
Despite decades of research, enzyme inhibitors for oral peptide delivery face several unresolved challenges.
Safety of chronic protease inhibition. Digestive proteases exist for a reason. Chronic inhibition of trypsin and chymotrypsin could impair protein digestion, alter gut microbiome composition, or trigger compensatory pancreatic hypersecretion. These concerns limit the dose and duration of co-administered enzyme inhibitors in clinical formulations.
Localization and timing. Enzyme inhibitors must be present at the right place and time, specifically at the site where the peptide drug is released, and in sufficient concentration to saturate local protease activity. If the inhibitor disperses or degrades before the peptide is released, protection fails. Formulation strategies that co-localize drug and inhibitor release (like nanoparticle co-encapsulation) address this but add manufacturing complexity.
The bioavailability ceiling. Even with optimized enzyme inhibitor formulations combined with enteric coatings and permeation enhancers, oral peptide bioavailability typically remains below 10% in preclinical models.[11] The approximately 1% bioavailability achieved by Rybelsus and Mycapssa, the only FDA-approved oral peptide drugs, suggests that current technology overcomes the enzymatic barrier only partially. Whether the remaining 90-99% of drug loss occurs at the enzymatic, mucosal, or epithelial barrier is not fully resolved.
The make-the-peptide-resistant alternative. For many peptide targets, engineering protease resistance directly into the molecule, through D-amino acid substitution, backbone modifications, or cyclization, may ultimately prove more practical than co-administering external enzyme inhibitors. This shifts the challenge from formulation science to medicinal chemistry but avoids the safety, timing, and localization problems inherent in protease inhibitor co-administration.
The Bottom Line
Enzyme inhibitors represent one layer in the multi-barrier approach required for oral peptide drug delivery. Classical protease inhibitors like aprotinin and soybean trypsin inhibitors can reduce peptide degradation in the GI tract, but they face their own stability challenges and must be co-localized with the drug at the site of absorption. Nanoparticle co-encapsulation and inherent peptide engineering (backbone modifications, D-amino acid substitution) offer alternative paths to protease resistance. Current oral peptide bioavailability remains below 10% even with these strategies, indicating that the enzymatic barrier is one of several obstacles that must be addressed simultaneously.